XML 46 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   $ 25,706 $ 10,412 $ 38,714 $ 23,086
Vaxcyte Agreements          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   846 703 1,493 1,378
Vaxcyte Agreements | Research and Development Services          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   650 567 1,297 1,071
Vaxcyte Agreements | Materials Supply          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   196 136 196 307
Collaboration and License Agreements and Supply Agreements          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   25,706 10,412 38,714 23,086
Collaboration and License Agreements and Supply Agreements | Bristol-Myers Squibb Company ("BMS")          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue     2,236   5,402
Collaboration and License Agreements and Supply Agreements | Merck Sharp & Dohme Corporation ("Merck")          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   8 140 14 2,693
Collaboration and License Agreements and Supply Agreements | Astellas Pharma Inc. ("Astellas")          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   24,752 7,333 36,137 13,605
Collaboration and License Agreements and Supply Agreements | Tasly Biopharmaceuticals Co., Ltd. ("Tasly")          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   5   975  
Collaboration and License Agreements and Supply Agreements | Vaxcyte          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   846 703 1,493 1,378
Collaboration and License Agreements and Supply Agreements | Ipsen Pharma SAS ("Ipsen")          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   95   95  
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name ''EMD Serono'')          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue         8
2020 Merck Master Services Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   8 140 14 2,693
2020 Merck Master Services Agreement | Research and Development Services          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue     79 6 204
2020 Merck Master Services Agreement | Materials Supply          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   8 61 8 2,489
Astellas License and Collaboration Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   24,752 7,333 36,137 13,605
Astellas License and Collaboration Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue $ 17,800 21,590 3,239 28,820 5,811
Astellas License and Collaboration Agreement | Research and Development Services          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   1,381 1,562 3,004 2,719
Astellas License and Collaboration Agreement | Financing Component on Unearned Revenue          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   1,758 $ 2,532 3,918 $ 5,075
Astellas License and Collaboration Agreement | Materials Supply          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   23   395  
Tasly License Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   5   975  
Tasly License Agreement | Research and Development Services          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   5   38  
Tasly License Agreement | Materials Supply          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue       937  
Ipsen Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   95   95  
Ipsen Agreement | Research and Development Services          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   18   18  
Ipsen Agreement | Materials Supply          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue   $ 77   $ 77